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BRIEF REPORTS
Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for
Spinal Muscular Atrophy: A Case Series
Deepa H. Chand, MD1,2, Craig Zaidman, MD2, Kapil Arya, MD3, Rachel Millner, MD3, Michelle A. Farrar, MBBS4,
Fiona E. Mackie, MBBS4, Natalie L. Goedeker, CPNP2, Vikas R. Dharnidharka, MD2, Raja Dandamudi, MD2,
and Sandra P. Reyna, MD1
Spinal muscular atrophy is treated with onasemnogene abeparvovec, which replaces the missing survival motor
neuron 1 gene via an adeno-associated virus vector. As of July 1, 2020, we had identified 3 infants who developed
thrombotic microangiopathy following onasemnogene abeparvovec. Early recognition and treatment of druginduced thrombotic microangiopathy may lessen mortality and morbidity. (J Pediatr 2021;231:265-8).

O

nasemnogene abeparvovec (Zolgensma) is an adenoassociated virus vector-based survival motor neuron 1
gene (SMN1) therapy, approved in the US, Europe,
Japan, Brazil, Israel, and Canada for the treatment of children
with spinal muscular atrophy (SMA). This therapy helps patients with SMA produce adequate SMN protein. It is a onetime intravenous infusion, administered concomitantly with
corticosteroid (followed by subsequent taper) to ameliorate
CD8+ T-cell–mediated immunity against adeno-associated virus capsids in host liver cells. The most common adverse reactions associated with onasemnogene abeparvovec reported in
clinical trials were elevated aminotransferases and vomiting.1
Warnings and precautions listed in the US prescribing information are acute serious liver injury, elevated aminotransferases, thrombocytopenia, and elevated troponin-I.1 Acute liver
injury can occur, and serial monitoring of liver function, platelets, and troponin-I concentrations are recommended.
Thrombotic microangiopathy (TMA) is characterized by
arteriole and capillary endothelial pathology and microvascular thrombosis. TMA presents clinically as a syndrome of
hemolytic anemia, thrombocytopenia, and acute kidney
injury. TMA is rare, occurring in 1.0-3.3 cases/million/
year,2,3 and can result from either genetic or acquired etiologies, such as exposure to toxins or infections and adverse
drug reactions,4 resulting in dysregulation of the alternative
pathway of complement. Some features of TMA overlap
with thrombotic thrombocytopenic purpura. However, activation of the alternate complement pathway and resultant
acute kidney injury differentiates TMA from thrombotic
thrombocytopenic purpura. Drug-induced TMA has been reported in association with many pharmaceutical products,
including vaccines, immunosuppressive agents, and antibiotics, as well as nonprescription substances, such as herbal
or alternative therapies.4

SMA
TMA
vWF

Spinal muscular atrophy
Thrombotic microangiopathy
von Willebrand factor

Although the actual mechanisms of TMA can vary, some
reports have suggested etiologies that include direct toxic effects (sometimes dose- and duration-dependent) as well as
immune-mediated reactions.4 Neurologic, cardiovascular,
and respiratory complications may occur. Treatment of
TMA includes withdrawal of the trigger agent, when possible,
and supportive care. Refractory or progressive cases also may
require plasmapheresis, dialysis, or anticomplement monoclonal antibody therapy, such as eculizumab.5
We report 3 children with new adverse reactions of TMA
following onasemnogene abeparvovec infusion and discuss
potential etiologies, with the aim to increase awareness to
optimize early recognition and treatment of TMA in these
children.

Methods
Using data from the Novartis Global Safety Database, we
conducted a search of all cases who were administered onasemnogene abeparvovec for SMA through July 1, 2020, using
the search terms “haemolytic uraemic syndrome,” “microangiopathic haemolytic anaemia,” “thrombotic microangiopathy,”
“thrombotic
thrombocytopenic
purpura,”
“microangiopathy,” “acute kidney injury,” and “haemolytic
anaemia” to identify any cases of TMA reported. This database includes safety information from the clinical trials,
managed access programs, and postmarketing (commercial)
settings. Three cases were identified and the corresponding
child neurologist and pediatric nephrologist from each center
were contacted to provide complementary data from the patient’s medical record in a deidentified manner.

From the 1Novartis Gene Therapies, Bannockburn, IL; 2Washington University
School of Medicine and St Louis Children’s Hospital, St Louis, MO; 3University of
Arkansas for Medical Sciences, Little Rock, AR; and 4Sydney Children’s Hospital
Randwick and School of Women’s and Children’s Health, University of New South
Wales, Australia (UNSW) Medicine, UNSW Sydney, Australia
D.C. and S.R. are Novartis Gene employees and hold stock entities.
0022-3476/ª 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jpeds.2020.11.054
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Table. Overview of thrombotic microangiopathy reports for SMA patients treated with onasemnogene abeparvovec
Variables
Country
Source of report
Demographics
Patient weight at dosing
Time to onset and first
symptom following
onasemnogene
abeparvovec
Nusinersen (most recent
dose)
Laboratory evidence of TMA
(baseline and following
onasemnogene
abeparvovec)
Hemoglobin

Case 1

Case 2

Case 3

US
RESTORE
5 mo, female
6.5 kg
7 d; hypertension, decreased urine
output

Australia
MAP
12 mo, female
12.1 kg
8 d; vomiting, reduced oral intake and
urine output

US
RESTORE
14 mo, female
8.7 kg
7 d; vomiting, dehydration

No

Yes (1 mo previously)

Yes (4 mo previously)

Baseline: 10.3 g/dL
Nadir: 7 g/dL (day 7)
Baseline: 503 k/mL
Nadir: 17 k/mL
Baseline: 0.1 mg/dL
Peak: 0.7 mg/dL
Peak: 4208 U/L
Protein and blood
Normal
Yes (influenza, Prevnar, and
Haemophilus influenzae type B, given
6 days after therapy
Aspiration pneumonia 4 d before dosing;
(Acinetobacter baumannii and
Pasteurella)
Second event of pneumonia 3 d after
dosing
Complement (C3)
1.1 g/L (ref 0.9-1.8)
Complement (C4)
0.07 (ref 0.15-0.57)
Bb fragment concentration
3.8 mg/L (ref <2.2)
Soluble C5b-9
0.9 mg/L (ref <0.3)
CH50
160 U eq/mL (ref >70)
FH autoantibody <50 AU (ref <200 AU)
Factor B
32.3 mg/dL (ref 22-50)
Factor H
369 mg/L (ref 180-420)
Factor I
34 mg/L (ref 16-40)
PRBC and platelet transfusions,
glucocorticoids, plasmapheresis,
diuretic for fluid overload,
antihypertensives

Baseline: 11.4 g/dL
Nadir: 9.6 g/dL (day 10)
Baseline: 378 k/mL
Nadir: 11 k/mL
Baseline 0.28mg/dL
Peak: 0.93 mg/dL
Peak: 2902 U/L
Protein and blood
Normal
Yes (10 days previously)

Baseline: 12.5 g/dL
Nadir: 6.1 g/dL (day 13)
Baseline: 506 k/mL
Nadir: 17 k/mL
Baseline: 0.1 mg/dL
Peak: 0.3 mg/dL
Peak: 1677 UL
Protein and blood
Normal
No

No

Urinary tract infection 3 d after
presentation (Escherichia coli)

Complement (C3)
0.62 g/L (ref 0.72-1.64)
Complement (C4)
0.05 g/L (ref 0.14-0.42)

Complement (C3)
57.8 mg/dL (ref 90-180)
Complement (C4)
0.13 g/L (ref 0.15-0.57),
Bb fragment concentration
2.8 mg/L (ref <2.2)
Soluble C5b-9
0.95 mg/L (ref <0.3)
CH50eq 134 U Eq/mL (ref >70)
Alternative pathway functional assay
62% (ref 50%–130%)
Hemolytic assay 0.6% (ref <3%)
FH autoantibody <50 AU (ref <200)
Factor B 30.7 mg/dL (22-50)
Factor H 330 mg/L (ref 180-420)
Factor I 35.5 mg/L (ref 18-44)

IV methylprednisolone, low-potassium
diet, furosemide for fluid overload,
antihypertensives, close clinical
and laboratory monitoring

Outcome (time from
diagnosis)

Recovered (2 wk) with persistent
hypertension

Recovered (4 wk)

Investigations concerning
potential predisposition
factors (hereditary or
acquired)

Functional complement assay with low
C4, and normal C3, CFH, I, neg CFHAb,
CH50, high C3b-9 (SMAC)
ADAMTS13 normal
No genetic testing completed
Stool and urine cultures negative

Functional complement assays normal
(C3, C4, CFH and I, neg anti-CFHAb,
CD46)
ADAMTS13 normal
No genetic testing completed
Stool and urine cultures negative

PRBC transfusion, methylprednisolone
followed by PO prednisolone, 25%
albumin, furosemide,
antihypertensives, eculizumab (single
dose)
Recovered (4 wk) with resolution of
hypertension and nephrotic syndrome
(3 mo)
Functional complement assay with low
C3 and C4, and normal CFH, I, neg
CFHAb, CH50
ADAMTS13 normal

Platelet
Creatinine
LDH
Urinalysis
PT, PTT, and INR
Vaccines within 1 mo of
onasemnogene
abeparvovec
Concurrent infections

Acute complement pathway
investigations (classic/
alternative) at
presentation of TMA

Treatments

ACTN4 gene and Heterozygous missense
variant p.G855R in FAT1 gene
Stool culture negative; urine culture + for
E coli

ACTN4, alpha-actinin-4; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; CFHAb, anti-complement factor H autoantibody; FH, factor H; INR, international normalized ratio;
IV, intravenous; LDH, lactate dehydrogenase; MAP, managed access program; PO, by mouth; PRBC, packed red blood cell; PT, prothrombin time; PTT, partial thromboplastin time; RESTORE, registry
of patients with spinal muscular atrophy receiving disease-modifying therapies.

266

Chand et al

April 2021

BRIEF REPORTS

Results

prednisolone), and other supportive therapy. TMA resolved
after 4 weeks and nephrotic-range proteinuria resolved
3 months after initial presentation, but hypertension persists.
Genetic testing showed heterozygous variants of unknown
significance in the actinin alpha-4 (ACTN4) and FAT atypical
cadherin 1 genes.

All 3 children received prednisolone 1 day prior to and for a
minimum of 30 days following treatment with 1.1  1014 vg/
kg of onasemnogene abeparvovec (Table).
Case 1
A 5-month-old female patient was treated with onasemnogene abeparvovec while hospitalized and undergoing treatment for aspiration pneumonia. Four days before dosing,
her sputum culture grew Proteus and Acinetobacter species.
She had another episode of pneumonia 3 days after onasemnogene infusion. Seven days after onasemnogene infusion,
she developed TMA with hemolytic anemia, hematuria, proteinuria, leukocytosis, thrombocytopenia, and severe hypertension. Renal ultrasound scan indicated diffuse increase in
cortical echogenicity bilaterally. The features of TMA
resolved within 2 weeks following plasmapheresis, except hypertension, which continues to persist 1 year later. Functional
TMA panel indicated evidence of complement pathway activation with no autoantibodies or abnormal complement
components. Genetic evaluation was not performed.
Case 2
A 12-month-old female patient was at her baseline with no
active infections when she received onasemnogene abeparvovec. Six days following onasemnogene abeparvovec infusion,
she developed twice-daily vomiting, although she tolerated
oral corticosteroid dosing. Eight days postinfusion, she presented with reduced oral intake and urine output and was hypertensive. Laboratory tests showed hemolysis, thrombocytopenia, transaminitis, and acute kidney injury with
microscopic hematuria and significant albuminuria. Renal ultrasound scan indicated increased echotexture and reduced corticomedullary differentiation. Echocardiogram indicated mild
pericardial effusion. However, by day 12 after infusion, she
began to improve with supportive care, and complete resolution occurred within 4 weeks.
Case 3
A 14-month-old female patient with a family history of
chronic kidney disease of unknown etiology in 2 seconddegree relatives received onasemnogene abeparvovec while
in her usual state of health without active infection. She
developed intermittent vomiting 1 day after infusion, which
persisted, although she tolerated oral corticosteroid dosing
with the use of ondansetron as needed. One week following
onasemnogene abeparvovec infusion, she presented with
dehydration, thrombocytopenia, hemolytic anemia, hypoalbuminemia, and acute kidney injury. Complement (C3)
was depressed. Initial urinalysis revealed proteinuria, but
urine culture was negative. The patient became febrile
3 days after initial presentation, and repeat urine culture at
that time grew Escherichia coli ³100 000 colonies/mL. Treatment included blood transfusion, eculizumab (single dose),
increased corticosteroids (5 mg/kg/day intravenous methyl-

Discussion
We have reported 3 children with SMA who developed TMA
following onasemnogene abeparvovec therapy. These cases
share several similarities. TMA developed approximately
1 week following onasemnogene abeparvovec infusion, 2 of
the 3 children suffered from vomiting, 2 of the 3 had previous
exposure to nusinersen, and 2 had infections with encapsulated organisms. Patient 1 had an infection preceding TMA
with a new infection shortly after infusion, and patient 3
developed an infection shortly after infusion. All 3 children
recovered from TMA. One recovered with supportive measures only. The other 2 resolved with additional therapies
such as plasmapheresis, increased corticosteroids, and/or
transfusions.
TMA is a syndrome of microvascular hemolysis and kidney injury that results from various etiologies, including
drug exposure. Several medications and herbal supplements
have been associated with TMA, including quinine, cyclosporine, and tacrolimus.4 Drug-induced TMA is theorized
to result from immune-mediated reactions or a dose-/duration-dependent direct toxic effect. Differentiating criteria
include early temporal association with drug administration
in the former as opposed to a delayed onset from a cumulative exposure in the latter. Our 3 patients developed TMA
approximately 1 week after administration, suggesting an
immune-mediated etiology.
Other causes and presentations of TMA include hemolytic
uremic syndrome resulting from shiga toxin-positive E coli;
thrombotic thrombocytopenic purpura resulting from a
reduction of ADAMTS13, the protease that cleaves von Willebrand factor (vWF); hereditary deficiencies in regulation of
coagulation or alternative complement pathways3; and a
wide variety of infectious pathogens, including encapsulated
organisms.6
In addition to exposure to onasemnogene abeparvovec,
each of the 3 patients had contributory factors that could
be putatively associated with TMA. Potential triggering factors include concurrent infection with encapsulated bacteria
and recent vaccine exposure. It is unknown what additional
risks to onasemnogene abeparvovec, if any, previous exposure to nusinersen confers. One patient had a gap of 4 months
between the most recent nusinersen exposure and treatment
with onasemnogene abeparvovec. Few studies have specifically addressed the safety of onasemnogene abeparvovec
following exposure to nusinersen, and vice versa.7,8 Two of
three children first developed vomiting, which may have
been an early symptom of TMA and potentially resulted in
inadequate prednisolone absorption. Two of the cases were

Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series
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associated with increased complement activation by the alternate pathway. One patient had received eculizumab, a humanized
monoclonal
antibody
targeted
against
complement C5, without subsequent improvement in symptoms.5
Whether children with SMA are at increased risk for TMA
is unknown. Children with SMA have been reported to have
coagulation abnormalities. Specifically, Wijngaarde et al reported data from 98 patients with SMA (types 1-4; median
age of 7.4 years), revealing significant prolongation of both
activated partial thromboplastin time and prothrombin
time, as well as increased platelet counts.9 The vWF antigen
and vWF activity were also significantly decreased, and this
was related to disease severity. No other significant abnormalities in coagulation factors II, V, VII, VIII, or X were
observed. Future studies are needed to elucidate the role of
genetic complement-mediated predisposing factors and
coagulation abnormalities in the pathogenesis of TMA in
SMA.
Nephrotic syndrome at presentation is not a classic feature
of TMA. Patient 3, who had persistent nephrotic syndrome,
did not have proteinuria or other signs of nephrotic syndrome during nusinersen treatment. She did, however,
have a family history of chronic kidney disease and was found
to have heterozygous ACTN4 and FAT1 variants of unknown
significance. These variants are not clearly pathogenic, but
ACTN4 mutations are associated with familial focal
segmental glomerulosclerosis.
Irrespective of contributory factors, these 3 case reports,
from approximately 500 patients exposed, indicate a plausible association between onasemnogene abeparvovec with
TMA based on their temporal association. Of note, TMA
has been reported following treatment with other gene therapies using an adeno-associated vector, including cases in a
Duchenne muscular dystrophy program.10 These cases have
been reported in a clinical trial of adeno-associated viral vector human gene therapy for Duchenne muscular dystrophy,
but case details are not available to determine whether there
are further similarities with our cases.10
Because thrombocytopenia is a key feature of TMA,
platelet counts should be monitored, as already recommended in the onasemnogene abeparvovec US prescribing information.1 If thrombocytopenia is present and there is a
clinical suspicion of TMA, further evaluation including he-
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moglobin and testing for hemolysis and renal dysfunction
(including urinalysis) also should be obtained. Early recognition of TMA is imperative, as TMA may require therapeutic
intervention
such
as
plasmapheresis,
dialysis,
or pharmacotherapy, to lessen associated morbidity and
mortality. n
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